People
A recent report by the U.S. Bureau of Labor Statistics and CBRE Research identified Seattle—which happens to be the BioSpace Bio Forest Hotbed—as the fastest-growing life science market in the top 10 from 2014 to 2017, with a greater than 17-percent growth.
Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, announces that it has appointed Didier Le Normand as Group CFO as well as General Manager of its recently opened Belgian subsidiary.
National Cancer Institute Director Norman “Ned” Sharpless will take over the role as acting commissioner of the FDA while the White House seeks a permanent replacement for the outgoing Scott Gottlieb.
With Cowen & Company’s 39th Annual Health Care Conference going on in Boston this week, a lot of stories in the biopharma industry are coming out. Here are a few highlights.
Shares of Zafgen are down more than 22 percent in premarket trading after the company announced Monday that it was suspending plans to develop a treatment for Prader-Willi syndrome.
The president’s proposed spending plan cuts $4.5 to $5.5 billion from the current budget of the National Institutes of Health, about an 11 percent decrease from 2019.
Back by popular demand, AmorChem, the innovative Quebec-based seed venture capital fund, is hosting the 5thedition of its KNOCK OUTTM Event, a challenge where the Contenders, academic researchers selected by AmorChem, duke it out in the ring against a panel of Heavyweight champions in order to qualify for a $500,000 financing from AmorChem.
On Friday, March 8, Bristol-Myers Squibb executives met with sell-side analysts to sell its $74 billion Celgene buyout.
The Federal Bureau of Prisons is investigating reports that Pharma Bro Martin Shkreli is using a contraband cellular telephone to continue to call the shots at his former company from prison.
As drugmakers continue to develop an understanding of what pain is to the human body, it helps drive the development of innovative manners to treat it that transcend addictive options such as opioids.
PRESS RELEASES